Download Systematic Identification Of Novel Diagnostic And Prognostic Tumor Biomarkers Based On Multi Omics Data Analysis Of Solid Tumors full books in PDF, epub, and Kindle. Read online free Systematic Identification Of Novel Diagnostic And Prognostic Tumor Biomarkers Based On Multi Omics Data Analysis Of Solid Tumors ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Ming Jun Zheng |
| Publisher | : Frontiers Media SA |
| Total Pages | : 342 |
| Release | : 2024-01-08 |
| Genre | : Science |
| ISBN | : 2832542565 |
| Author | : Chunquan Li |
| Publisher | : Frontiers Media SA |
| Total Pages | : 272 |
| Release | : 2023-03-02 |
| Genre | : Science |
| ISBN | : 2832516246 |
| Author | : Liang Cheng |
| Publisher | : Frontiers Media SA |
| Total Pages | : 349 |
| Release | : 2023-02-02 |
| Genre | : Medical |
| ISBN | : 283251314X |
| Author | : Susan Costantini Alfredo Budillon |
| Publisher | : MDPI |
| Total Pages | : 294 |
| Release | : 2021-02-12 |
| Genre | : Medical |
| ISBN | : 3039439774 |
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
| Author | : Sudhir Srivastava |
| Publisher | : John Wiley & Sons |
| Total Pages | : 338 |
| Release | : 2017-06-05 |
| Genre | : Medical |
| ISBN | : 111846883X |
Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information and hopefully also inspiration to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers
| Author | : Giampietro Gasparini |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 335 |
| Release | : 2008-01-17 |
| Genre | : Medical |
| ISBN | : 159259915X |
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
| Author | : Pallaval Veera Bramhachari |
| Publisher | : Springer Nature |
| Total Pages | : 238 |
| Release | : 2020-07-21 |
| Genre | : Medical |
| ISBN | : 981154431X |
This book describes various novel biomarkers for the early diagnosis of gastrointestinal (GI) cancers. It also highlights recent advances in understanding the role of molecular markers and biomarkers, such as volatile biomarkers, serum biomarkers, predictive and prognostic molecular markers for the early detection of GI cancers. Further, it discusses novel biomarkers, including circulating microRNAs, serum microRNA and plasma microRNA in GI cancer. The book presents breakthrough technologies like ultra-sensitive nano-chips, nanosensors, nanodevices, biosensors, electrochemical biosensors, optical biosensors, DNA biosensors, synthetic biology devices, and 'omics' technologies for the early diagnosis of gastrointestinal cancer. In addition it examines the potential of genome-wide association studies, big data analytics, computation biology, systems biology, and nanotechnology for early diagnostics and therapeutics for gastrointestinal cancer, with a focus on personalized cancer treatment. The book is a valuable source for researchers and clinicians engaged in detection and diagnosis of gastrointestinal cancers.
| Author | : Debmalya Barh |
| Publisher | : CRC Press |
| Total Pages | : 992 |
| Release | : 2014-01-30 |
| Genre | : Medical |
| ISBN | : 1466584289 |
Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis Presents noninvasive early molecular markers in urological cancers Describes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myeloma Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 112 |
| Release | : 2006-11-18 |
| Genre | : Medical |
| ISBN | : 0309101344 |
Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.
| Author | : Kamla Kant Shukla |
| Publisher | : Springer |
| Total Pages | : 341 |
| Release | : 2019-03-15 |
| Genre | : Medical |
| ISBN | : 981135877X |
This book aims to bring together a broad variety of examples of the role of pharmacogenomics in current drug development, uncovering dynamic concentration-dependent drug responses on biological systems to understand pharmacodynamics responses in human cancer where genetic lesions serve as tumor markers and provide a basis for cancer diagnosis. The book describes methods and protocols applied in molecular diagnostics. It offers pathologists and researchers providing molecular diagnostic services an array of the most recent and readily accessible reference to compare methods and techniques. Highlights include the molecular diagnosis of genetic aberrations by quantitative polymerase reaction (qPCR), sequence-specific oligonucleotide arrays, next-generation sequencing (NGS), CGH arrays-and methodologies directed at the detection of epigenetic events, high-throughput nucleic acid and protein arrays, direct sequencing and FISH-based methodologies, currently used in the diagnosis of solid tumors. The book also includes an innovative line of treatment in relation to the molecular prognosis, diagnosis and pharmacogenomics in the actual practice of clinical findings at molecular levels. The book covers the applications of numerous genetic testing methodologies; in approximately the chronological order of discovery and high-throughput diagnosis using advanced genomic approaches to identify such genes, in the search for novel drug targets and/or key determinants of drug reactions. It also promotes a wider understanding of molecular diagnostics among physicians, medical students, and scientists in academics, industry and corporate world.
